Aimee M. Hunter, Ph.D.
Affiliations: | University of California, Los Angeles, Los Angeles, CA |
Area:
stress, psychosomatic illness, psychopathologyGoogle:
"Aimee Hunter"Mean distance: 17.17 (cluster 19) | S | N | B | C | P |
Parents
Sign in to add mentor| Thomas R. Minor | grad student | 2001 | UCLA | |
| (Glutamate and escape performance in a neurometabolic stress conception of helplessness.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Cook IA, Hunter AM, Caudill MM, et al. (2020) Prospective testing of a neurophysiologic biomarker for treatment decisions in major depressive disorder: The PRISE-MD trial. Journal of Psychiatric Research. 124: 159-165 |
| Cook IA, Congdon E, Krantz DE, et al. (2019) Time Course of Changes in Peripheral Blood Gene Expression During Medication Treatment for Major Depressive Disorder. Frontiers in Genetics. 10: 870 |
| Corlier J, Wilson A, Hunter AM, et al. (2019) Changes in Functional Connectivity Predict Outcome of Repetitive Transcranial Magnetic Stimulation Treatment of Major Depressive Disorder. Cerebral Cortex (New York, N.Y. : 1991) |
| Hunter AM, Minzenberg MJ, Cook IA, et al. (2019) Concomitant medication use and clinical outcome of repetitive Transcranial Magnetic Stimulation (rTMS) treatment of Major Depressive Disorder. Brain and Behavior. e01275 |
| Hunter AM, Nghiem TX, Cook IA, et al. (2017) Change in Quantitative EEG Theta Cordance as a Potential Predictor of Repetitive Transcranial Magnetic Stimulation Clinical Outcome in Major Depressive Disorder. Clinical Eeg and Neuroscience. 1550059417746212 |
| Leuchter MK, Donzis EJ, Cepeda C, et al. (2017) Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington's Disease: Are They Fit-for-Purpose for Treatment Development? Frontiers in Neurology. 8: 91 |
| Kobayashi B, Cook IA, Hunter AM, et al. (2017) Can neurophysiologic measures serve as biomarkers for the efficacy of repetitive transcranial magnetic stimulation treatment of major depressive disorder? International Review of Psychiatry (Abingdon, England). 1-17 |
| Leuchter A, Espinoza R, Suthana N, et al. (2017) Synergistic effects of ketamine and theta burst stimulation in the treatment of major depressive disorder (MDD) Brain Stimulation. 10: 492 |
| Leuchter AF, Hunter AM, Jain FA, et al. (2016) Escitalopram but not placebo modulates brain rhythmic oscillatory activity in the first week of treatment of Major Depressive Disorder. Journal of Psychiatric Research. 84: 174-183 |
| Scanlon GC, Jain FA, Hunter AM, et al. (2016) Neurophysiologic Correlates of Headache Pain in Subjects With Major Depressive Disorder. Clinical Eeg and Neuroscience |